Literature DB >> 11403952

Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain.

A Takashima1, M Murayama, K Yasutake, H Takahashi, M Yokoyama, K Ishiguro.   

Abstract

P35 or its truncated fragment p25 is required for cyclin dependent kinase (Cdk)5 activation. It has been reported that p25 is accumulated in the brain of Alzheimer's disease (AD) patients and that p25/Cdk5 induces high phosphorylation of tau and apoptosis in cultured neurons (Nature 402 (1999) 615). Our investigation of AD brain did not show specific accumulation of p25. Exposure to Ca ionophore (A23187) at 10(-6) M induced p25 accumulation in rat primary hippocampal neurons, causing neuronal death without showing hyperphosphorylation of tau. Transgenic mice expressing p25 showed the accumulation of p25 but neither hyperphosphorylation of tau nor neuronal death was shown in these mice. The feature of these mice was the progression of cell growth in pituitary gland. These results suggest that overexpression of p25 lead to the activation of cell cycle but not to the direct phosphorylation of tau.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403952     DOI: 10.1016/s0304-3940(01)01864-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

Review 1.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

2.  Cdk5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease.

Authors:  Katherine R Sadleir; Robert Vassar
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

3.  Regulation of Kalirin by Cdk5.

Authors:  Xiaonan Xin; Yanping Wang; Xin-ming Ma; Panteleimon Rompolas; Henry T Keutmann; Richard E Mains; Betty A Eipper
Journal:  J Cell Sci       Date:  2008-07-15       Impact factor: 5.285

Review 4.  The Role of Cdk5 in Alzheimer's Disease.

Authors:  Shu-Lei Liu; Chong Wang; Teng Jiang; Lan Tan; Ang Xing; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-07-31       Impact factor: 5.590

5.  Novel genetic tools reveal Cdk5's major role in Golgi fragmentation in Alzheimer's disease.

Authors:  Kai-Hui Sun; Yolanda de Pablo; Fabien Vincent; Emmanuel O Johnson; Angela K Chavers; Kavita Shah
Journal:  Mol Biol Cell       Date:  2008-05-14       Impact factor: 4.138

Review 6.  Cdk5 as a drug target for the treatment of Alzheimer's disease.

Authors:  Lit-Fui Lau; Patricia A Seymour; Mark A Sanner; Joel B Schachter
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

7.  Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice.

Authors:  Mala V Rao; Mary Kate McBrayer; Jabbar Campbell; Asok Kumar; Audrey Hashim; Henry Sershen; Philip H Stavrides; Masuo Ohno; Michael Hutton; Ralph A Nixon
Journal:  J Neurosci       Date:  2014-07-09       Impact factor: 6.167

Review 8.  In vitro cultured neurons for molecular studies correlating apoptosis with events related to Alzheimer disease.

Authors:  Nadia Canu; Pietro Calissano
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

9.  p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.

Authors:  Janice L Hallows; Robert E Iosif; Rebecca D Biasell; Inez Vincent
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

10.  p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide.

Authors:  Kathleen I Seyb; Sabah Ansar; Guibin Li; Jennifer Bean; Mary L Michaelis; Rick T Dobrowsky
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.